Results From the CheckMate 143 Clinical Trial: Stalemate or New Game Strategy for Glioblastoma Immunotherapy?

JAMA Oncol. 2020 Jul 1;6(7):987-989. doi: 10.1001/jamaoncol.2020.0857.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Bevacizumab
  • Glioblastoma* / therapy
  • Humans
  • Immunotherapy
  • Neoplasm Recurrence, Local
  • Nivolumab

Substances

  • Bevacizumab
  • Nivolumab